Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares
Potential Biomea Fusion, Inc. ( NASDAQ:BMEA ) shareholders may wish to note that the Independent Director, Michael ...
Biomea Fusion: Recent Rally May Not Last, Despite Upcoming Data Catalysts
I highlight potential of Biomea Fusion's diabetes drug amid competition, advises caution with stock due to risks. Read more ...
bovnews3d
Truist Just Upgraded Biomea Fusion Inc (BMEA) Stock—What Does This Mean for Investors?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 22.46% ...
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.’s (NASDAQ:BMEA) ongoing Phase 1/2 clinical trials of the ...
bovnews6d
The Biomea Fusion Inc Stock Thriller: Decoding the Mystery Behind BMEA’s Recent Movements
On Thursday, Biomea Fusion Inc (BMEA) stock saw a modest uptick, ending the day at $9.57 which represents a slight increase of $0.80 or 9.12% from the prior close of $8.77. The stock opened at $8.98 ...
Fintel on MSN6d
Rodman & Renshaw Upgrades Biomea Fusion (BMEA)
Fintel reports that on September 26, 2024, Rodman & Renshaw upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from ...
Fintel on MSN5d
Truist Securities Upgrades Biomea Fusion (BMEA)
Fintel reports that on September 27, 2024, Truist Securities upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from ...
Buy Rating Affirmed for Biomea Fusion with Promising BMF-219 Clinical and Regulatory Developments
Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated ...
Biomea Fusion Hold Rating: FDA Clearance and Increased Price Target Amid Cautious Optimism
Barclays analyst Peter Lawson has reiterated their neutral stance on BMEA stock, giving a Hold rating yesterday. Peter Lawson has given his ...
US FDA lifts clinical hold on Biomea's diabetes trials after safety review
The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for ...
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s ...
ETF Daily News7d
Biomea Fusion (NASDAQ:BMEA) Upgraded by Rodman & Renshaw to Buy
Biomea Fusion (NASDAQ:BMEA – Get Free Report) was upgraded by stock analysts at Rodman & Renshaw from a “neutral” rating to a “buy” rating in a research note issued on Thursday ...